RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Study overview

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in Post-Acute Sequelae of SARS-CoV-2 infection (PASC) participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Collaborators and Investigators

Kanecia Obie Zimmerman,

Christopher Grainger, MD, STUDY_CHAIR, Duke Clinical Research Institute

Cyndya Shibao, MD, STUDY_CHAIR, Vanderbilt University Medical Center

Peter Novak, MD, STUDY_CHAIR, Harvard

Pam Taub, MD, STUDY_CHAIR, University of California, San Diego

Tae Chung, MD, STUDY_CHAIR, Johns Hopkins University

Study Record Dates

2026-03